Oncotarget

Research Papers:

A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio

Qiang Zhao, Sheng Chen and Ji-Feng Feng _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:103535-103542. https://doi.org/10.18632/oncotarget.21989

Metrics: PDF 1135 views  |   HTML 1986 views  |   ?  


Abstract

Qiang Zhao1,2, Sheng Chen1,2 and Ji-Feng Feng1,2

1Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, P.R.China

2Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, P.R. China

Correspondence to:

Ji-Feng Feng, email: [email protected], [email protected]

Keywords: esophageal squamous cell carcinoma, c-reactive protein, neutrophil lymphocyte ratio, cancer-specific survival, prognosis

Received: July 10, 2017     Accepted: September 23, 2017     Published: October 20, 2017

ABSTRACT

Background: We initially proposed a novel inflammation-based prognostic index, named neutrophil lymphocyte ratio/albumin ratio (NLR/Alb), for predicting the postoperative survival in esophageal squamous cell carcinoma (ESCC).

Materials and methods: A retrospective study of 329 cases with resectable ESCC was included. The optimal cut-off values were evaluated by X-tile program. The 5-year cancer-specific survival (CSS) was calculated by Kaplan–Meier method. Cox regression analyses were performed to evaluate the prognostic factors.

Results: The optimal cut-off value was 0.1 for NLR/Alb according to the X-tile program. There was a significantly better 5-year CSS in patients with NLR/Alb ≤ 0.1 than patients with NLR/Alb > 0.1 (39.1% vs. 11.0%, P < 0.001). According to multivariate analyses, NLR/Alb (P = 0.001) was an independent prognostic factor.

Conclusions: The NLR/Alb is a novel and usefull predictive factor in patients with ESCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21989